Innocan Pharma Q1 net loss widens to USD 886,000; revenue falls to USD 6.47 million

  • Innocan Pharma posted a net loss of USD 886,000, widening from USD 229,000 a year earlier.
  • Revenue fell to USD 6.47 million from USD 7.8 million, while operating results swung to a loss of USD 786,000 from profit of USD 489,000.
  • Selling, marketing and distribution expenses edged down to USD 5.52 million from USD 5.7 million, while general and administrative costs climbed to USD 971,000 from USD 744,000.
  • Cash and cash equivalents slipped to USD 6.63 million at March 31, 2026 from USD 6.69 million at Dec. 31, 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innocan Pharma Ltd. published the original content used to generate this news brief on May 27, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.